Determination of the Occlusion Pressure in Lymphatic VesselsEarly Phase 1OcclusionNCT02359578
Determining Occlusion Pressure in Lymphatic Vessels
A Early Phase 1 study testing Indocyanine Green in people with Determination of the Occlusion Pressure in Lymphatic Vessels, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.
Trial summary
The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic systolic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Determination of the Occlusion Pressure in Lymphatic Vessels
- What is being tested?
- Indocyanine Green
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteBelgium
- Study dates
- Aug 2014to Jan 2015
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy volunteers
- Written informed consent signed
Who cannot join
- Coronary disease
- Pregnancy
- Allergy to iodine or to shellfish
- Breastfeeding
- Advanced renal impairment
- Minors
Show all 11Show fewer
- Thyroid pathology
- Primary and secondary lymphedema anywhere on the body
- Oncologic history
- Familial lymphedema
- Previous surgery on the studied member, causing risk of a subclinical lymphedema
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Occlusion Pressure of Superficial Lymphatics in the Upper Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach
The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic systolic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Actually, knowledge about this physiological parameter is incomplete because of the lack of technology. Former measurement techniques of the lymphatic systolic pressure in the living healthy man were invasive and too complex to be interpreted.
The lymphatic occlusion pressure has to be clarified because lymphedema treatment, concerning the pressure to be applied on the edematous tissue is still based on controversial concepts.
Read more
On one hand, techniques such as Manual Lymphatic Drainage, sustain the necessity to apply a very low pressure in order to avoid the squeezing of superficial lymph vessels. On the other hand sustainers of Intermittent Compression Therapy advocate the necessity to apply relatively high pressure to obtain a decongesting effect. These completely opposite opinions triggered us to study lymphatic pressure more thoroughly.
Lymphofluoroscopy (emerging imaging technique in the field of lymphology) is now used since 3 years by the promoters of this study to visualize the architecture of the superficial lymphatic network and the progression of the lymph inside the highlighted vessels. This technique will be used in the present (prospective and multicentric) study to observe the effect of a pressure applied on the limb on the displacement of the lymph, and then to determine the occlusion pressure of the lymphatic vessels.
Read the detailed description
Injection of contrast agent Indocyanine Green (ICG) is a tricarbocyanine dye that is commonly used for hepatic, cardiovascular, plastic surgery and ophthalmology applications. It is usually injected intravenously at a dose comprised between 0.1 and 0.5 mg/kg. After administration, ICG binds to plasmatic proteins, lipoproteins and lipids, and is thereafter rapidly and completely cleared from blood by the liver. ICG is excited and emits fluorescence in the near-infrared (around 760 nm).
In this study, we will suspend ICG in 25 ml pure water and subsequently diluted with pure water to reach a final concentration of 1 mg/ml. Each subject will receive a subcutaneous injection of 0.2 ml of diluted ICG (e.i. 200µg), using a hypodermic needle. We will standardize the injection point and inject ICG subcutaneously in the first interdigital space, according to the injection method used for lymphoscintigraphy. In this way, we highlight systematically the same area of the superficial lymphatic network.
We know that in the upper limbs, lateralization or handedness coincides with functional (and/or anatomical) asymmetries. To avoid any bias, the injected arm in healthy patients will be randomized tossing heads or tails.
Fluorescence images acquisition After injection, the injection sites will be covered with tape to avoid camera oversaturation, and to avoid spreading of ICG on the skin and undesirable fluorescent background on the images. To obtain fluorescence imaging of arm lymphatic flow, a near-infrared fluorescence imaging system will be used (Photo Dynamic Eye, or PDE camera from Hammamatsu Photonics - Japan). The camera is maintained in a fix position, 15 cm above the investigation field, by a holding system from Noga Tools. The amplified analogic signal is transformed into a digital signal by a converter from Terratec (Model Grabster AV 450 MX) and transferred to a monitor, which allows to visualize lymphatic network and lymph flow in real-time. Images will be recorded on a dedicated external hard disk drive Iomega, model MDHDU.
The session will take place in a dark room, to allow NIR fluorescence images acquisition.
Specific manual lymphatic drainage, developed by the first author and his team under NIRF feedback, is performed immediately after the injection, during the whole experimental session in order to be sure that the examined lymphatic vessels permanently contain lymph. The lymph is propelled with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff. This optimized manual lymphatic drainage will be performed for 3 minutes in order to easily detect the superficial lymphatic vessels at the volar region of the arm and to mark the area of interest. The MLD is standardized by the first author for this experiment, and composed by a continuous and repeated sequence, executed from distal to proximal, of 3 "fill up" maneuvers realized on the injection point, succeeded by 2 "wash out" maneuvers realized from the injection point to the limit line before the cuff. Then, two fluorescent lines are drawn on the skin in a distance of 50 mm in order to limit the space of reference.
The cuff of the transparent sphygmomanometer is placed in the middle of the arm.
The sphygmomanometer is connected to a pressure meter, indicating mm of Mercury (Testo® 510 Digital Manometer precision 0.1mmHg.).
The PDE camera will be maintained perpendicularly on the major axis of the arm, at the level of the middle of the cuff.
In order to make sure that observed lymphatic vessels contain lymph, the fluorescent lymph is propelled during all the experience with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff.
- First step: as baseline we record and observe the lymphatic flow under the un-inflated cuff.
- Second step: the cuff is inflated at 30mmHg, images are recorded during three lymph flow passages.
Three independent observers are present. They control the three passages of lymph in order to give the consent to go over to the next pressure step.
- Third step: We increase the inflated pressure in steps of 10 mmHg recording images at each increase (waiting for three passages of lymph at each step).
The experiment is completed as soon as we visually note the complete stop of lymph progression under the transparent cuff. At that moment, the pressure is reduced by 10mmHg in order to validate the return of the lymph flow. After this step, we observe and record images of the lymphatic vessel from the injection point up to the root of the limb.
- Being tested
- Indocyanine Green
- Keywords
- lymphatic system, occlusion pressure, Indocyanine Green
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Indocyanine GreenDrug
Also called ICG
Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
| Study group | Role | What they receive |
|---|---|---|
| Lymphatic occlusion pressure | Experimental | injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted. Receives: Drug: Indocyanine Green |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lymph flow active or not depending on the pressure applied
Study of the influence of an applied pressure on this upper limb on the progression of the lymph in this limb, using a sphygmomanometer.
Measured: 1 minute
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2015 (estimated)
- Study startAug 2014
- Primary completionNov 2014
- Study completionJan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Determination of the Occlusion Pressure in Lymphatic VesselsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Saint Pierre
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jean-Paul Belgrado, Principal investigator, CHU St-Pierre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02359578
- Sponsor's protocol ID
- LY-OCCL-PRESSURE-1
- Acronym
- Occlusion
- Status last verified
- Feb 2015
- First submitted
- 5 Feb 2015
- Last updated
- 13 Feb 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Occlusion Pressure of Superficial Lymphatics in the Upper Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach
- ClinicalTrials.gov ID
- NCT02359578
- Acronym / sponsor ID
- Occlusion / LY-OCCL-PRESSURE-1
- Keywords
- lymphatic system, occlusion pressure, Indocyanine Green
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire Saint PierreUniversity, hospital or other
- Study start
- Aug 2014
- Primary completion
- Nov 2014 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 10 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic systolic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Actually, knowledge about this physiological parameter is incomplete because of the lack of technology. Former measurement techniques of the lymphatic systolic pressure in the living healthy man were invasive and too complex to be interpreted.
The lymphatic occlusion pressure has to be clarified because lymphedema treatment, concerning the pressure to be applied on the edematous tissue is still based on controversial concepts.
On one hand, techniques such as Manual Lymphatic Drainage, sustain the necessity to apply a very low pressure in order to avoid the squeezing of superficial lymph vessels. On the other hand sustainers of Intermittent Compression Therapy advocate the necessity to apply relatively high pressure to obtain a decongesting effect. These completely opposite opinions triggered us to study lymphatic pressure more thoroughly.
Lymphofluoroscopy (emerging imaging technique in the field of lymphology) is now used since 3 years by the promoters of this study to visualize the architecture of the superficial lymphatic network and the progression of the lymph inside the highlighted vessels. This technique will be used in the present (prospective and multicentric) study to observe the effect of a pressure applied on the limb on the displacement of the lymph, and then to determine the occlusion pressure of the lymphatic vessels.
Detailed description
Injection of contrast agent Indocyanine Green (ICG) is a tricarbocyanine dye that is commonly used for hepatic, cardiovascular, plastic surgery and ophthalmology applications. It is usually injected intravenously at a dose comprised between 0.1 and 0.5 mg/kg. After administration, ICG binds to plasmatic proteins, lipoproteins and lipids, and is thereafter rapidly and completely cleared from blood by the liver. ICG is excited and emits fluorescence in the near-infrared (around 760 nm).
In this study, we will suspend ICG in 25 ml pure water and subsequently diluted with pure water to reach a final concentration of 1 mg/ml. Each subject will receive a subcutaneous injection of 0.2 ml of diluted ICG (e.i. 200µg), using a hypodermic needle. We will standardize the injection point and inject ICG subcutaneously in the first interdigital space, according to the injection method used for lymphoscintigraphy. In this way, we highlight systematically the same area of the superficial lymphatic network.
We know that in the upper limbs, lateralization or handedness coincides with functional (and/or anatomical) asymmetries. To avoid any bias, the injected arm in healthy patients will be randomized tossing heads or tails.
Fluorescence images acquisition After injection, the injection sites will be covered with tape to avoid camera oversaturation, and to avoid spreading of ICG on the skin and undesirable fluorescent background on the images. To obtain fluorescence imaging of arm lymphatic flow, a near-infrared fluorescence imaging system will be used (Photo Dynamic Eye, or PDE camera from Hammamatsu Photonics - Japan). The camera is maintained in a fix position, 15 cm above the investigation field, by a holding system from Noga Tools. The amplified analogic signal is transformed into a digital signal by a converter from Terratec (Model Grabster AV 450 MX) and transferred to a monitor, which allows to visualize lymphatic network and lymph flow in real-time. Images will be recorded on a dedicated external hard disk drive Iomega, model MDHDU.
The session will take place in a dark room, to allow NIR fluorescence images acquisition.
Specific manual lymphatic drainage, developed by the first author and his team under NIRF feedback, is performed immediately after the injection, during the whole experimental session in order to be sure that the examined lymphatic vessels permanently contain lymph. The lymph is propelled with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff. This optimized manual lymphatic drainage will be performed for 3 minutes in order to easily detect the superficial lymphatic vessels at the volar region of the arm and to mark the area of interest. The MLD is standardized by the first author for this experiment, and composed by a continuous and repeated sequence, executed from distal to proximal, of 3 "fill up" maneuvers realized on the injection point, succeeded by 2 "wash out" maneuvers realized from the injection point to the limit line before the cuff. Then, two fluorescent lines are drawn on the skin in a distance of 50 mm in order to limit the space of reference.
The cuff of the transparent sphygmomanometer is placed in the middle of the arm.
The sphygmomanometer is connected to a pressure meter, indicating mm of Mercury (Testo® 510 Digital Manometer precision 0.1mmHg.).
The PDE camera will be maintained perpendicularly on the major axis of the arm, at the level of the middle of the cuff.
In order to make sure that observed lymphatic vessels contain lymph, the fluorescent lymph is propelled during all the experience with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff.
- First step: as baseline we record and observe the lymphatic flow under the un-inflated cuff.
- Second step: the cuff is inflated at 30mmHg, images are recorded during three lymph flow passages.
Three independent observers are present. They control the three passages of lymph in order to give the consent to go over to the next pressure step.
- Third step: We increase the inflated pressure in steps of 10 mmHg recording images at each increase (waiting for three passages of lymph at each step).
The experiment is completed as soon as we visually note the complete stop of lymph progression under the transparent cuff. At that moment, the pressure is reduced by 10mmHg in order to validate the return of the lymph flow. After this step, we observe and record images of the lymphatic vessel from the injection point up to the root of the limb.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lymphatic occlusion pressure | Experimental | Drug: Indocyanine Greeninjection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Healthy volunteers
- Written informed consent signed
Key exclusion criteria (11 listed)
- Coronary disease
- Pregnancy
- Allergy to iodine or to shellfish
- Breastfeeding
- Advanced renal impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Indocyanine GreenAlso: ICGSubcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm | Drug | Lymphatic occlusion pressure |
Primary outcome
Lymph flow active or not depending on the pressure applied
Time frame: 1 minute
Study of the influence of an applied pressure on this upper limb on the progression of the lymph in this limb, using a sphygmomanometer.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2015.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean-Paul Belgrado principal investigator
CHU St-Pierre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Indocyanine Green in people with Determination of the Occlusion Pressure in Lymphatic Vessels, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lymph flow active or not depending on the pressure applied (time frame: 1 minute). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2015.